<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Biochemical Engineering</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD746859-F11A-4988-A207-4B0DD3EAA955"><gtr:id>DD746859-F11A-4988-A207-4B0DD3EAA955</gtr:id><gtr:name>Sutro Biopharma</gtr:name><gtr:address><gtr:line1>310 Utah Avenue</gtr:line1><gtr:line2>Suite 150</gtr:line2><gtr:postCode>CA 94080</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11C45689-C208-49DC-A95B-1B971827AEB3"><gtr:id>11C45689-C208-49DC-A95B-1B971827AEB3</gtr:id><gtr:name>Merck &amp; Co Inc</gtr:name><gtr:address><gtr:line1>Merck &amp; Co Inc</gtr:line1><gtr:line2>One Merck Drive</gtr:line2><gtr:line4>Whitehouse Station</gtr:line4><gtr:line5>NJ 08889-0100</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F950F20E-5FE6-4848-8045-5B7B40A30590"><gtr:id>F950F20E-5FE6-4848-8045-5B7B40A30590</gtr:id><gtr:name>BIA Separations</gtr:name><gtr:address><gtr:line1>Mirce 21</gtr:line1><gtr:postCode>SI-5270</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4F1E0A44-0778-4833-9405-0D5C2309D672"><gtr:id>4F1E0A44-0778-4833-9405-0D5C2309D672</gtr:id><gtr:name>Centre for Process Innovation Limited</gtr:name><gtr:address><gtr:line1>Wilton Centre
Wilton</gtr:line1><gtr:city>Redcar</gtr:city><gtr:postCode>TS10 4RF</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D31C478D-680E-46CA-8A7F-8CD1698914FE"><gtr:id>D31C478D-680E-46CA-8A7F-8CD1698914FE</gtr:id><gtr:name>BioIndustry Association</gtr:name><gtr:address><gtr:line1>7th Floor Southside</gtr:line1><gtr:line2>105 Victoria Street</gtr:line2><gtr:postCode>SW1E 6QT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7D9D87A2-E892-4364-8ACE-DAF9FF7D0B52"><gtr:id>7D9D87A2-E892-4364-8ACE-DAF9FF7D0B52</gtr:id><gtr:name>BioPharm Services</gtr:name><gtr:address><gtr:line1>22 Wycombe End</gtr:line1><gtr:postCode>HP9 1NB</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A96A8BAB-09EE-47A0-9332-F08CD4DB48A9"><gtr:id>A96A8BAB-09EE-47A0-9332-F08CD4DB48A9</gtr:id><gtr:name>Wyatt Technology UK Ltd</gtr:name><gtr:address><gtr:line1>Wyatt Technology UK Ltd</gtr:line1><gtr:line2>14 Redshank Close</gtr:line2><gtr:postCode>CB9 0PB</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5CD05437-C117-429B-AB98-7D5B889521A5"><gtr:id>5CD05437-C117-429B-AB98-7D5B889521A5</gtr:id><gtr:name>Allergan Limited (UK)</gtr:name><gtr:address><gtr:line1>Marlow International</gtr:line1><gtr:line2>The Parkway</gtr:line2><gtr:postCode>SL7 1YL</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6090002B-C548-4F19-BA43-49C1FFB7FFEC"><gtr:id>6090002B-C548-4F19-BA43-49C1FFB7FFEC</gtr:id><gtr:name>deltaDOT Ltd</gtr:name><gtr:address><gtr:line1>London BioScience Innovation Centre</gtr:line1><gtr:line2>2 Royal College Street</gtr:line2><gtr:postCode>NW1 0NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/14E0E5BF-E946-4743-B7CE-0B743670EF9B"><gtr:id>14E0E5BF-E946-4743-B7CE-0B743670EF9B</gtr:id><gtr:name>Perceptive Engineering Limited</gtr:name><gtr:address><gtr:line1>Daresbury Innovation Centre</gtr:line1><gtr:line2>Keckwick Lane</gtr:line2><gtr:postCode>WA4 4FS</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1E67A5CF-5B8A-45C0-BCF3-9176C174FDFB"><gtr:id>1E67A5CF-5B8A-45C0-BCF3-9176C174FDFB</gtr:id><gtr:name>GlaxoSmithKline PLC</gtr:name><gtr:address><gtr:line1>980 Great West Road</gtr:line1><gtr:postCode>TW8 9GS</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/29827560-DF13-40B1-9FB4-5DF34FC12BAB"><gtr:id>29827560-DF13-40B1-9FB4-5DF34FC12BAB</gtr:id><gtr:name>Albumedix Ltd</gtr:name><gtr:address><gtr:line1>Castle Court</gtr:line1><gtr:line2>59 Castle Boulevard</gtr:line2><gtr:postCode>NG7 1FD</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EDB67137-AF95-475C-954C-8EA1517069D6"><gtr:id>EDB67137-AF95-475C-954C-8EA1517069D6</gtr:id><gtr:name>Nat Inst for Bio Standards and Control</gtr:name><gtr:address><gtr:line1>Blanche Lane</gtr:line1><gtr:line2>South Mimms</gtr:line2><gtr:line4>Potters Bar</gtr:line4><gtr:line5>Hertfordshire</gtr:line5><gtr:postCode>EN6 3QG</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/47CE491B-8DF0-40F5-B5AE-ECCB94527E60"><gtr:id>47CE491B-8DF0-40F5-B5AE-ECCB94527E60</gtr:id><gtr:name>Eli Lilly S.A. - Irish Branch</gtr:name><gtr:address><gtr:line1>Dunderrow</gtr:line1><gtr:line2>Kinsale, Co</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8D289B04-57AE-49B3-8280-F8D20BB17CE9"><gtr:id>8D289B04-57AE-49B3-8280-F8D20BB17CE9</gtr:id><gtr:name>Assoc of the British Pharm Ind (ABPI)</gtr:name><gtr:address><gtr:line1>7th floor</gtr:line1><gtr:line2>Southside</gtr:line2><gtr:line3>105 Victoria Street</gtr:line3><gtr:postCode>SW1E 6QT</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3CE01BF9-4D85-4CB7-AAFF-90B2AE789E1A"><gtr:id>3CE01BF9-4D85-4CB7-AAFF-90B2AE789E1A</gtr:id><gtr:name>UCB Celltech</gtr:name><gtr:address><gtr:line1>208 Bath Road</gtr:line1><gtr:line4>Slough</gtr:line4><gtr:postCode>SL1 3WE</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF011913-612C-412B-B74C-1D844B2BE084"><gtr:id>EF011913-612C-412B-B74C-1D844B2BE084</gtr:id><gtr:name>Fujifilm Diosynth Biotechnologies</gtr:name><gtr:address><gtr:line1>Belasis Avenue</gtr:line1><gtr:postCode>TS23 1LH</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CF18E78D-4964-4DB5-971F-4C95EF3A52B9"><gtr:id>CF18E78D-4964-4DB5-971F-4C95EF3A52B9</gtr:id><gtr:name>Puridify LTD</gtr:name><gtr:address><gtr:line1>Basement 93</gtr:line1><gtr:line2>Camden Street</gtr:line2><gtr:postCode>SG1 2FX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/84EC36D9-AAC8-496A-B69B-F9DE2213B154"><gtr:id>84EC36D9-AAC8-496A-B69B-F9DE2213B154</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5DE06059-09E1-4A48-8CC6-A80FFDFBE118"><gtr:id>5DE06059-09E1-4A48-8CC6-A80FFDFBE118</gtr:id><gtr:name>Francis Biopharma Ltd</gtr:name><gtr:address><gtr:line1>38 Longmeadow</gtr:line1><gtr:line2>Riverhead</gtr:line2><gtr:postCode>TN13 2QY</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99FE562A-11FA-44A2-B83F-11182FE26780"><gtr:id>99FE562A-11FA-44A2-B83F-11182FE26780</gtr:id><gtr:name>Roche Diagnostics GmbH</gtr:name><gtr:address><gtr:line1>Roche Diagnostics GmbH</gtr:line1><gtr:line2>Nonnenwald 2</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/45555183-99CB-4B93-BB81-CE9DDF06CF7E"><gtr:id>45555183-99CB-4B93-BB81-CE9DDF06CF7E</gtr:id><gtr:name>Lonza Biologics</gtr:name><gtr:address><gtr:line1>228 Bath Road</gtr:line1><gtr:line4>Slough</gtr:line4><gtr:postCode>SL1 4DX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B44E5899-5EC1-41EF-9E13-CD88F38E2ADD"><gtr:id>B44E5899-5EC1-41EF-9E13-CD88F38E2ADD</gtr:id><gtr:name>Merck KGaA,</gtr:name><gtr:address><gtr:line1>Headquarters of the Merck Group</gtr:line1><gtr:line2>Frankfurter Str. 250</gtr:line2><gtr:postCode>D-64293</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/297A15CD-210D-4958-851F-CC2B1915A665"><gtr:id>297A15CD-210D-4958-851F-CC2B1915A665</gtr:id><gtr:name>Purolite International Ltd</gtr:name><gtr:address><gtr:line1>Cowbridge Road</gtr:line1><gtr:line4>Pontyclun</gtr:line4><gtr:line5>Mid Glamorgan</gtr:line5><gtr:postCode>CF72 8YL</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8B397931-E408-4411-9815-5BECA5DCEFFA"><gtr:id>8B397931-E408-4411-9815-5BECA5DCEFFA</gtr:id><gtr:name>LGC Limited</gtr:name><gtr:address><gtr:line1>Queens Road</gtr:line1><gtr:postCode>TW11 0LY</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A7708DB6-C1F2-4D0D-B044-91611DEEC5E5"><gtr:id>A7708DB6-C1F2-4D0D-B044-91611DEEC5E5</gtr:id><gtr:name>Medicines Manufacturing Ind Partnership</gtr:name><gtr:address><gtr:line1>7th floor Southside</gtr:line1><gtr:line2>105 Victoria Street</gtr:line2><gtr:postCode>SW1E 6QT</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A38855B8-20F0-4C36-8BD0-014FDCBE9DDB"><gtr:id>A38855B8-20F0-4C36-8BD0-014FDCBE9DDB</gtr:id><gtr:name>Knowledge Transfer Network</gtr:name><gtr:address><gtr:line1>FIRST FLOOR, ST. JAMES' HOUSE
ST. JAMES' SQUARE</gtr:line1><gtr:city>Cheltenham</gtr:city><gtr:postCode>GL50 3PR</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9568331E-B037-4ED9-B6C7-E37B9C088784"><gtr:id>9568331E-B037-4ED9-B6C7-E37B9C088784</gtr:id><gtr:name>Catapult Cell Therapy</gtr:name><gtr:address><gtr:line1>12th Floor Tower Wing</gtr:line1><gtr:line2>Guy's Hospital</gtr:line2><gtr:line3>Great Maze Pond</gtr:line3><gtr:postCode>SE1 9RT</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D92716D0-081B-4976-A3CF-2E591C175698"><gtr:id>D92716D0-081B-4976-A3CF-2E591C175698</gtr:id><gtr:name>Novo Nordisk A/S</gtr:name><gtr:address><gtr:line1>Hagedornsvej 1</gtr:line1><gtr:postCode>2820</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C82B81BF-EC82-4E94-946F-AA35415C8602"><gtr:id>C82B81BF-EC82-4E94-946F-AA35415C8602</gtr:id><gtr:name>Oxford BioMedica (UK) Ltd</gtr:name><gtr:address><gtr:line1>Oxford BioMedica (UK) Ltd</gtr:line1><gtr:line2>Medawar Centre</gtr:line2><gtr:line3>Oxford Science Park</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX4 4GA</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7ABD91C-FB14-492C-B456-3376E8ED538C"><gtr:id>C7ABD91C-FB14-492C-B456-3376E8ED538C</gtr:id><gtr:name>FloDesign Sonics</gtr:name><gtr:address><gtr:line1>380 Main Street Wilbraham</gtr:line1><gtr:postCode>01095</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C48D48CE-BE47-4A68-8898-A6F6CEB3A085"><gtr:id>C48D48CE-BE47-4A68-8898-A6F6CEB3A085</gtr:id><gtr:name>TrakCel</gtr:name><gtr:address><gtr:line1>11 Raleigh Walk</gtr:line1><gtr:line2>Brigantine Place</gtr:line2><gtr:line3>Waterfront 2000</gtr:line3><gtr:postCode>CF10 4LN</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2EC5A92D-11A1-441B-BEC9-EEE301A015B9"><gtr:id>2EC5A92D-11A1-441B-BEC9-EEE301A015B9</gtr:id><gtr:name>Autolus Ltd</gtr:name><gtr:address><gtr:line1>Forest House</gtr:line1><gtr:line2>Depot Road (off Wood Lane)</gtr:line2><gtr:postCode>W12 7RP</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3F6AAEA4-757C-4BCB-B46E-CE072405C616"><gtr:id>3F6AAEA4-757C-4BCB-B46E-CE072405C616</gtr:id><gtr:name>Reneuron Ltd</gtr:name><gtr:address><gtr:line1>Reneuron Ltd</gtr:line1><gtr:line2>10 Nugent Road</gtr:line2><gtr:line3>Surrey Research Park</gtr:line3><gtr:line4>Guildford</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>GU2 1AF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D61E9AA1-C89A-47C5-B6B1-1FAD2ACB6ABE"><gtr:id>D61E9AA1-C89A-47C5-B6B1-1FAD2ACB6ABE</gtr:id><gtr:name>Sartorius Stedim UK Limited</gtr:name><gtr:address><gtr:line1>Longmead Business Park</gtr:line1><gtr:line2>Blenheim Road</gtr:line2><gtr:postCode>KT19 9QQ</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/941C2E74-C576-49DA-9987-CE40EF8A611D"><gtr:id>941C2E74-C576-49DA-9987-CE40EF8A611D</gtr:id><gtr:name>Pfizer</gtr:name><gtr:address><gtr:line1>235 East 42nd Street</gtr:line1><gtr:postCode>10017</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ABB71A96-C879-4399-92F0-73B1C419419D"><gtr:id>ABB71A96-C879-4399-92F0-73B1C419419D</gtr:id><gtr:name>BioLogicB, LLC</gtr:name><gtr:address><gtr:line1>P.O. Box 559</gtr:line1><gtr:postCode>11713</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0219D92F-D98F-4D4A-8071-CDCD5FD0FB9C"><gtr:id>0219D92F-D98F-4D4A-8071-CDCD5FD0FB9C</gtr:id><gtr:name>Tillingbourne Consulting Limited</gtr:name><gtr:address><gtr:line1>Tythebarn, East Shalford Lane</gtr:line1><gtr:postCode>GU4 8AS</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A7ED50E2-8773-452E-9B1F-0AC4FDDB5AD5"><gtr:id>A7ED50E2-8773-452E-9B1F-0AC4FDDB5AD5</gtr:id><gtr:firstName>Barry</gtr:firstName><gtr:surname>Lennox</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B2136587-49F8-408D-AB7A-986D39148745"><gtr:id>B2136587-49F8-408D-AB7A-986D39148745</gtr:id><gtr:firstName>Ivan</gtr:firstName><gtr:surname>Wall</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/46690F5A-4376-4585-947D-FC76085E6DF5"><gtr:id>46690F5A-4376-4585-947D-FC76085E6DF5</gtr:id><gtr:firstName>Laura</gtr:firstName><gtr:surname>Diaz Anadon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DC90A2BE-C009-482F-BD40-FA2EF60F8C63"><gtr:id>DC90A2BE-C009-482F-BD40-FA2EF60F8C63</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Aylott</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DA78ACB5-9A2A-4125-B571-650E8671C3D4"><gtr:id>DA78ACB5-9A2A-4125-B571-650E8671C3D4</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Thomas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5ABCC1B3-C66F-4A46-BB05-5D273D93E00F"><gtr:id>5ABCC1B3-C66F-4A46-BB05-5D273D93E00F</gtr:id><gtr:firstName>Farlan</gtr:firstName><gtr:otherNames>Singh</gtr:otherNames><gtr:surname>Veraitch</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EDE67D99-9688-44DB-AB92-25AE106B2D7C"><gtr:id>EDE67D99-9688-44DB-AB92-25AE106B2D7C</gtr:id><gtr:firstName>Suzanne</gtr:firstName><gtr:surname>Farid</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0EAB19CE-E446-4D6D-86A5-0959FD9A5ED3"><gtr:id>0EAB19CE-E446-4D6D-86A5-0959FD9A5ED3</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:surname>Titchener-Hooker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2E0BBB9D-2AE8-4368-A89A-665317171804"><gtr:id>2E0BBB9D-2AE8-4368-A89A-665317171804</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Dalby</gtr:surname><gtr:orcidId>0000-0002-0980-8167</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A8ACADD2-6AB0-4C00-BE1E-C69D90DBBE5A"><gtr:id>A8ACADD2-6AB0-4C00-BE1E-C69D90DBBE5A</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:otherNames>Gilbert</gtr:otherNames><gtr:surname>Bracewell</gtr:surname><gtr:orcidId>0000-0003-3866-3304</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B44E197F-C6F3-47A8-AB9A-D7AC25D598E1"><gtr:id>B44E197F-C6F3-47A8-AB9A-D7AC25D598E1</gtr:id><gtr:firstName>Juergen</gtr:firstName><gtr:surname>Branke</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B8277CE4-2ACC-473D-A5B0-5E15DFB615A6"><gtr:id>B8277CE4-2ACC-473D-A5B0-5E15DFB615A6</gtr:id><gtr:firstName>Nilay</gtr:firstName><gtr:surname>Shah</gtr:surname><gtr:orcidId>0000-0002-8906-6844</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1C0FE342-06DC-44B6-82A6-BDD87D6AD780"><gtr:id>1C0FE342-06DC-44B6-82A6-BDD87D6AD780</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Morris</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7B8301B4-DFD4-4B23-87B3-D7D669780DA0"><gtr:id>7B8301B4-DFD4-4B23-87B3-D7D669780DA0</gtr:id><gtr:firstName>Nicolas</gtr:firstName><gtr:surname>Szita</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FP006485%2F1"><gtr:id>11E069BD-6E77-469D-870D-B3CDC3EE7B6A</gtr:id><gtr:title>FUTURE TARGETED HEALTHCARE MANUFACTURING HUB</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/P006485/1</gtr:grantReference><gtr:abstractText>By 2025 targeted biological medicines, personalised and stratified, will transform the precision of healthcare prescription, improve patient care and quality of life. Novel manufacturing solutions have to be created if this is to happen. This is the unique challenge we shall tackle. The current &amp;quot;one-size-fits-all&amp;quot; approach to drug development is being challenged by the growing ability to target therapies to only those patients most likely to respond well (stratified medicines), and to even create therapies for each individual (personalised medicines). Over the last ten years our understanding of the nature of disease has been transformed by revolutionary advances in genetics and molecular biology.

Increasingly, treatment with drugs that are targeted to specific biomarkers, will be given only to patient populations identified as having those biomarkers, using companion diagnostic or genetic screening tests; thus enabling stratified medicine. For some indications, engineered cell and gene therapies are offering the promise of truly personalised medicine, where the therapy itself is derived at least partly from the individual patient. In the future the need will be to supply many more drug products, each targeted to relatively small patient populations. Presently there is a lack of existing technology and infrastructure to do this, and current methods will be unsustainable. These and other emerging advanced therapies will have a critical role in a new era of precision targeted-medicines. All will have to be made economically for healthcare systems under extreme financial pressure. The implications for health and UK society well-being are profound

There are already a small number of targeted therapies on the market including Herceptin for breast cancer patients with the HER2 receptor and engineered T-cell therapies for acute lymphoblastic leukaemia. A much greater number of targeted therapies will be developed in the next decade, with some addressing diseases for which there is not currently a cure. To cope, the industry will need to create smarter systems for production and supply to increasingly fragmented markets, and to learn from other sectors. Concepts will need to address specific challenges presented by complex products, of processes and facilities capable of manufacture at smaller scales, and supply chains with the agility to cope with fluctuating demands and high levels of uncertainty.

Innovative bioprocessing modes, not currently feasible for large-scale manufacturing, could potentially replace traditional manufacturing routes for stratified medicines, while simultaneously reducing process development time. Pressure to reduce development costs and time, to improve manufacturing efficiency, and to control the costs of supply, will be significant and will likely become the differentiating factor for commercialisation.

We will create the technologies, skill-sets and trained personnel needed to enable UK manufacturers to deliver the promise of advanced medical precision and patient screening. The Future Targeted Healthcare Manufacturing Hub and its research and translational spokes will network with industrial users to create and apply the necessary novel methods of process development and manufacture. Hub tools will transform supply chain economics for targeted healthcare, and novel manufacturing, formulation and control technologies for stratified and personalised medicines. The Hub will herald a shift in manufacturing practice, provide the engineering infrastructure needed for sustainable healthcare. The UK economy and Society Wellbeing will gain from enhanced international competitiveness.</gtr:abstractText><gtr:potentialImpactText>WHO WILL BENEFIT FROM THE RESEARCH
The impact of the Future Targeted Healthcare Manufacturing Hub will extend far beyond the Hub itself with significant benefits for manufacturing companies, healthcare providers, UK citizens and the economy as a whole.

Companies
The stratified protein medicines and cellular therapies of the future cannot be made or developed using the manufacturing technologies in use for current therapies. A radical step-change and innovation to deliver the economically viable processes is required. UK companies will benefit from new process technologies designed to deliver these step changes with the necessary cost performance and speed of development. The companies will also benefit from new decision support tools that will provide a robust framework for selecting processes and manufacturing options reducing the risk of misallocating significant cost and time. The researchers trained in the Hub will have the skills and experience required by industry to transfer and implement these technologies in practice.

Healthcare Providers
It is recognised that in some diseases only 20-30% of patients are effectively treated by the standard treatment care and that there may be serious adverse reactions among those that are not. This represents a very significant wasted resource in time and materials for healthcare providers under enormous pressure to reduce costs. Targeted medicines are designed to match effective treatments to patients but this promise can only be delivered if new therapies can be developed more quickly than currently and if they have greater cost effectiveness including lower manufacturing costs than existing medicines. The processes and decision-support tools developed in the Hub will enable product manufacturers to meet these challenges.

Patients
Faster development and more economic processes for targeted therapeutics will allow the promise of precision to be realised for the patient. They will enable patients to access promptly new stratified and personalised therapies, in some cases for diseases not currently treated and they will reduce ineffective treatments and adverse side effects.

UK Economy
The UK has a strong established pharmaceutical industry and a growing number of new companies developing new protein and cellular therapies. The development of new processes and tools to guide selection of processes and manufacturing option will enable this sector to commercialise successfully their rapidly increasing research effort in targeted medicines and increase the GVA of this part of the pharmaceutical industry.

HOW WILL THEY BENEFIT FROM THE RESEARCH
The Grand Challenge research in the hub will create new process technologies to address key manufacturing challenges identified following extensive discussion with the industry. Additionally the Hub with create new decision-support tools that will be used to accelerate the development and optimisation of manufacturing processes at appropriate scales. These tools will address the complexity of new clinical trial structures and increasingly decentralised manufacturing.

User-led feasibility projects with companies of the User Group, part of the Hub's platform research, will help test and evaluate these products. The Hub will have IP arrangements designed to achieve rapid exploitation and broad uptake and will involve three Catapults to facilitate translation of the technologies developed to market. 18 PDRAS, 28 CDT, 23 PhD and 14 EngD researchers on projects aligned to the hub will be trained with the process development skills required by industry. The Hub will engage with regulators to ensure they are briefed and informed on the emerging new technologies to allow appropriate regulatory strategies to be developed and put in place.

The successful commercialisation of new targeted biological medicines by companies will strengthen the UK manufacturing community with direct impacts on people employed and UK wealth generated.</gtr:potentialImpactText><gtr:fund><gtr:end>2023-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2017-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>10317089</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>271A9DE5-D8C8-4396-AF4F-37AD67CEEF30</gtr:id><gtr:title>A guide to manufacturing CAR T cell therapies.</gtr:title><gtr:parentPublicationTitle>Current opinion in biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bc6c4d0873a148a0e2873d3563dad95"><gtr:id>3bc6c4d0873a148a0e2873d3563dad95</gtr:id><gtr:otherNames>Vormittag P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0958-1669</gtr:issn><gtr:outcomeId>5a9fedb402a518.64594537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC1CE770-643A-4EC3-93DD-00AB49244AAE</gtr:id><gtr:title>Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/614499d6dfd60e0aac13fcc6156c92cd"><gtr:id>614499d6dfd60e0aac13fcc6156c92cd</gtr:id><gtr:otherNames>Yang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>5a83a1c8acab58.84508681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA1271C9-67B3-4933-8034-A0B287718C1F</gtr:id><gtr:title>Cell free protein synthesis: a viable option for stratified medicines manufacturing?</gtr:title><gtr:parentPublicationTitle>Current Opinion in Chemical Engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d86b84b7624bd2a69a28b2d9cddc650"><gtr:id>3d86b84b7624bd2a69a28b2d9cddc650</gtr:id><gtr:otherNames>.Ogonah O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>22113398</gtr:issn><gtr:outcomeId>5aaa86385bb2e6.03139701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABF05423-7166-452D-9014-56BF000B0029</gtr:id><gtr:title>Enhancing cell and gene therapy manufacture through the application of advanced fluorescent optical sensors (Review).</gtr:title><gtr:parentPublicationTitle>Biointerphases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b71b7d7025497fdf93c20b63aa89a8dd"><gtr:id>b71b7d7025497fdf93c20b63aa89a8dd</gtr:id><gtr:otherNames>Harrison RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1559-4106</gtr:issn><gtr:outcomeId>5a352d921d7d10.67009991</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E261969-EC40-4FAF-9DDD-54983DBE1C32</gtr:id><gtr:title>An integrated experimental and economic evaluation of cell therapy affinity purification technologies.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06e8b865074854ce15327f1bb8d5cfb1"><gtr:id>06e8b865074854ce15327f1bb8d5cfb1</gtr:id><gtr:otherNames>Weil BD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>5a83a1c88e9986.36070180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7047556D-D4C9-437E-A65A-FA43AE6569CA</gtr:id><gtr:title>Two strategies to engineer flexible loops for improved enzyme thermostability.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e213ed81f1f914c04a65d68b018bdb4"><gtr:id>7e213ed81f1f914c04a65d68b018bdb4</gtr:id><gtr:otherNames>Yu H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a14059d28df09.57874429</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43BCB8B2-F945-4841-AD19-BF0F1A819536</gtr:id><gtr:title>Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dff8199fec6dbd0350e8f93dc486863d"><gtr:id>dff8199fec6dbd0350e8f93dc486863d</gtr:id><gtr:otherNames>Pollock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>5a83a1c7bce795.30074378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E921181-1F3B-46C1-ADF5-BEF028C73DE6</gtr:id><gtr:title>T-Values and Unfolded Fraction Can Predict Aggregation Rates for Granulocyte Colony Stimulating Factor Variant Formulations but Not under Predominantly Native Conditions.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b8b501485f620456c0b15ece1cb914d"><gtr:id>2b8b501485f620456c0b15ece1cb914d</gtr:id><gtr:otherNames>Robinson MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>5a3529a281bbf1.06674105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DCFE7A9-CFB7-4CE7-B1A9-EB0304908DEA</gtr:id><gtr:title>Experimentally integrated dynamic modelling for intuitive optimisation of cell based processes and manufacture</gtr:title><gtr:parentPublicationTitle>Biochemical Engineering Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96aa440190b56e95435e4d1482c46e2b"><gtr:id>96aa440190b56e95435e4d1482c46e2b</gtr:id><gtr:otherNames>Stacey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a821c7d8dfc74.10614400</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>943DC1C8-8AA6-437A-B19F-BC6CF4A0B647</gtr:id><gtr:title>A roadmap for cost-of-goods planning to guide economic production of cell therapy products.</gtr:title><gtr:parentPublicationTitle>Cytotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78322abf441d70500266abb0717b5b0a"><gtr:id>78322abf441d70500266abb0717b5b0a</gtr:id><gtr:otherNames>Lipsitz YY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1465-3249</gtr:issn><gtr:outcomeId>5a83a1c82af4c1.38904632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEBF0CF8-DD3C-4781-B7C5-F242AC1EAD99</gtr:id><gtr:title>A new lot sizing and scheduling heuristic for multi-site biopharmaceutical production</gtr:title><gtr:parentPublicationTitle>Journal of Heuristics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2974edeb8bfb71774911df4337e32089"><gtr:id>2974edeb8bfb71774911df4337e32089</gtr:id><gtr:otherNames>Oyebolu F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>15729397 13811231</gtr:issn><gtr:outcomeId>5a8f4d00d877f7.64368952</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/P006485/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>17F21DBC-4946-4262-AD07-9914F6EA12F7</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Bioengineering</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>FA25733D-A456-4A1B-9D5C-7119577368D9</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Manufacturing</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>99E0B904-CAB5-4511-AFB3-AA6D2B171F97</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Process engineering</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>9C387DA5-CD5F-43E4-AA74-82CBF4DB6617</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Bioprocess Engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>DC402B6E-3B84-4EAB-AED8-9CB51552A1CE</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Macro-molecular delivery</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>2E2E80C2-8D14-44CE-A971-37A9ACC4B244</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Manufact. Enterprise Ops&amp; Mgmt</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>ABBD3B7F-5022-4513-82D6-5414B965FAB3</gtr:id><gtr:percentage>30</gtr:percentage><gtr:text>Manufacturing Machine &amp; Plant</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>